Literature DB >> 2023218

Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta.

W D Xu1, E C Leroy, E A Smith.   

Abstract

To determine whether enhanced matrix synthesis by systemic sclerosis (SSc) fibroblasts in vitro is due to increased responsiveness to transforming growth factor-beta (TGF-beta), fibronectin release by SSc and normal fibroblasts (7 pairs) was measured at various concentrations of TGF-beta. In the absence of TGF-beta, SSc fibroblasts released 30 +/- 22% more fibronectin than normal fibroblasts. While both SSc and normal fibroblasts increased fibronectin release at all concentrations of TGF-beta tested, the percentage increases were not statistically greater for the SSc fibroblasts even though 4 of the SSc fibroblasts strains were selectively sensitive to low concentrations of TGF-beta. TGF-beta increased cell numbers of both SSc and normal strains equally. Our data confirm abnormal regulation of fibronectin gene expression in SSc fibroblasts and suggest increased sensitivity to TGF-beta by some SSc fibroblast strains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023218

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

2.  MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma.

Authors:  Honglin Zhu; Yisha Li; Shunlin Qu; Hui Luo; Yaou Zhou; Yanping Wang; Hongjun Zhao; Yunhui You; Xianzhong Xiao; Xiaoxia Zuo
Journal:  J Clin Immunol       Date:  2012-02-04       Impact factor: 8.317

3.  Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masatoshi Jinnin; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Hypertrophic osteoarthropathy: endothelium and platelet function.

Authors:  F Silveri; R De Angelis; F Argentati; D Brecciaroli; S Muti; C Cervini
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 5.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

6.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.

Authors:  M R Hussein; H I Hassan; E R M Hofny; M Elkholy; N A Fatehy; A E A Abd Elmoniem; A M Ezz El-Din; O A Afifi; H G Rashed
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

7.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

8.  Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

10.  Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma.

Authors:  B Eckes; C Mauch; G Hüppe; T Krieg
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.